Pompe disease Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight

1. Pompe Disease incidence is usually estimated to be 1:40,000 live birth in worldwide. 2. Pompe disease prevalence is estimated to be 1 in 40,000, with the disease affecting males and females equally. 3. Pompe disease prevalence is approximately 1 in 28,000 in the United States. Get a free sample page:https://bit.ly/2MNdjW6 Pompe disease symptoms are caused by missing or insufficient amounts of an enzyme called acid alpha-glucosidase (GAA). Although, there is currently no cure,...
LAS VEGAS, (informazione.it - comunicati stampa - salute e benessere)

Get a free sample page: https://bit.ly/2MNdjW6

Pompe disease symptoms are caused by missing or insufficient amounts of an enzyme called acid alpha-glucosidase (GAA). Although, there is currently no cure, different Pompe disease treatment options can help to ease Pompe disease symptoms.

Most patients require supportive therapy to address the Pompe disease symptoms that include respiratory and cardiac problems, physical disability, and difficulty swallowing. Some patients may require a mechanical ventilator during respiratory infections or at night. Physical and occupational therapy can improve patients' muscle strength and help them to learn to use canes or walkers if necessary. Speech therapy and usage of feeding tubes are some of the other components. Prior to the arrival of Enzyme replacement therapy (ERT) in 2006, patients were primarily dependent on Supportive Treatment comprising of respiratory support, ambulatory support, physiotherapy and/or dietary treatment.

The increasing awareness of the Pompe disease assisted by organizational support along with the high prices of Enzyme Replacement therapies (and expanded approvals) is expected to fuel the Pompe disease market size during the forecasted period of 2019-2028.

The expected launch of emerging therapies is believed to create a positive impact on the Pompe disease market size in the upcoming years.

Some of the companies are:-

Get a free demo of the report: https://bit.ly/2MNdjW6

Table of contents

1. Pompe Disease Report Introduction

2. Pompe Disease Market Overview at a Glance

3. Pompe Disease Disease Background and Overview

4. Diagnostic approaches for identification of Pompe Disease

5. Pompe Disease Epidemiology and Patient Population

6. Pompe Disease Country- Wise Epidemiology

6.1. United States

6.2. EU-5

6.2.1.Assumptions and Rationale

6.2.2.Germany

6.2.3.France

6.2.4.Italy

6.2.5.Spain

6.2.6.United Kingdom

6.3. Japan

7. Pompe Disease Treatments & Medical Practices

8. Pompe Disease Marketed Products

8.1. Myozyme/ Lumizyme: Sanofi Genzyme

9. Pompe Disease Emerging Therapies

9.1. Key Cross Competition

9.2. AT-GAA: Amicus Therapeutics

11. Country-Wise Market Analysis 7MM

11.1. United States Market Size

11.2. Germany Market Size

11.3. France Market Size

11.4. United Kingdom Market Size

11.5. Spain Market Size

11.7. Japan Market Size

12. Market Drivers

13. Market Barriers

14. Pompe Disease Report Methodology

15. DelveInsight Capabilities

16. Disclaimer

17. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Related reports:

Pompe Disease - Pipeline Insight, 2019

"Pompe Disease - Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across Pompe Disease. A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type.

Pompe Disease - Epidemiology Forecast to 2028

DelveInsight's Pompe Disease- Epidemiology Forecast, 2028" report provides a comprehensive analysis of the Pompe Disease   epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

Contact us:
Shruti Thakur
[email protected]
+91-9650213330

Ufficio Stampa
 PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom
Allegati
Slide ShowSlide Show
Non disponibili